Navigation Links
Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin

PHILADELPHIA, Dec. 13, 2011 /PRNewswire/ -- Tarsa Therapeutics today confirmed that it is planning to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) in the second half of 2012 for OSTORA™, the company's oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis. This follows a formal pre-NDA dialogue with the FDA that verified the results from Tarsa's Phase III ORACAL trial and the requirements for regulatory approval, including agreement on key elements of the submission. The study design and specific endpoints had previously been agreed in a Special Protocol Assessment with the FDA. 

"Our recent dialogue with the FDA was very productive and we are on track to submit an NDA for OSTORA as a treatment for postmenopausal osteoporosis in the second half of 2012," noted David Brand, Chief Executive Officer of Tarsa. "Our revised timeline for filing the NDA partly reflects Emisphere Technologies' recent report of negative Phase III trial results for their oral calcitonin product partnered with Novartis. This development affords us the time to ensure that we assemble the highest quality NDA submission with the goal of maximizing our chances for timely regulatory review and approval." 

At the 2011 Annual Meeting of the American Society for Bone and Mineral Research earlier this year, Tarsa reported positive efficacy and safety results from its year-long Phase III ORACAL trial showing that OSTORA achieved all of the trial's efficacy endpoints and demonstrated statistically significant superiority to both placebo and nasal calcitonin spray in increasing bone mass density at the lumbar spine.  In this trial, the safety profile of OSTORA did not substantially differ from nasal calcitonin or placebo and the majority of adverse events were mild or moderate.

Tarsa's oral calcitonin is also being assessed in a one-year double-blind Phase II study comparing the OSTORA tablet to placebo in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  The study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population. 

Tarsa is developing its OSTORA oral calcitonin under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.

About Tarsa Therapeutics

Tarsa Therapeutics is a venture-backed clinical stage biotechnology company developing OSTORA™, an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.  Calcitonin has a long history of safety and efficacy and availability of an oral form is expected to generate wider use.  Tarsa has reported positive efficacy and safety results from the Phase III ORACAL trial of its oral calcitonin tablet in the treatment of postmenopausal osteoporosis, and a Phase II osteoporosis prevention trial is underway.  Tarsa is based in Philadelphia, PA.  For more information, visit


GendeLLindheim BioCom Partners
Barbara Lindheim                                                                                  

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
(Date:11/30/2015)... Dec. 1, 2015  An interventional radiology technique shows promise ... preliminary results of a study being presented today at the ... America (RSNA). --> ... decades by interventional radiologists as a way to stop bleeding ... as a means of treating obesity is new. ...
Breaking Biology Technology:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
Breaking Biology News(10 mins):